Are ERBB2 mutations a ‘ready for routine use’ target in patients with metastatic breast cancer?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Are ERBB2 mutations a ‘ready for routine use’ target in patients with metastatic breast cancer?

Published:2023-10 Issue:5 Volume:8 Page:101832
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Grinda T.,Pistilli B.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference20 articles.

1. The European Society for Medical Oncology (ESMO) precision medicine glossary;Yates;Ann Oncol,2018

2. Activating HER2 mutations in HER2 gene amplification negative breast cancer;Bose;Cancer Discov,2013

3. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies;Nayar;Nat Genet,2019

4. Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer;Croessmann;Clin Cancer Res,2019

5. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity;Hanker;Cancer Cell,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3